Go online to PeerView.com/KNX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, leading melanoma experts discuss the role of immunotherapy as a standard adjuvant option in stage III/IV—and potentially stage II—disease and the potential of neoadjuvant checkpoint blockade in certain resectable settings (eg, macroscopic stage III disease). Real-world examples of immunotherapy treatment in resectable disease and the foundational and emerging science that continues to inform surgical oncology care are also presented. Upon completion of this activity, participants should be better able to: Cite current evidence and guideline recommendations for the use of immunotherapy in resectable stage III/IV melanoma, Describe efficacy and safety data surrounding the use of immunotherapy as adjuvant or neoadjuvant therapy in resectable melanoma, including in stage II or stage III macroscopic disease, respectively, Integrate adjuvant or neoadjuvant immunotherapy into the management of patients with resectable melanoma, including those with BRAF-positive or BRAF-negative disease, Manage immune-related adverse events in patients with melanoma receiving immunotherapy in conjunction with surgery.
View all episodes
